CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases

被引：28

作者：

Reijneveld, JC

Brandsma, D

Boogerd, W

Bonfrer, JGM

Kalmijn, S

Voest, EE

Geurts-Moespot, A

Visser, MC

Taphoorn, MJB

机构：

[1] VU Univ, Med Ctr, Dept Neurol, NL-1007 MB Amsterdam, Netherlands

[2] Univ Utrecht, Med Ctr, Dept Neurol, Utrecht, Netherlands

[3] Univ Utrecht, Med Ctr, Lab Med Oncol, Div Med Oncol, Utrecht, Netherlands

[4] Univ Utrecht, Med Ctr, Julius Ctr Gen Practice & Patient Oriented Res, Utrecht, Netherlands

[5] Univ Utrecht, Med Ctr, Dept Chem Endocrinol, Utrecht, Netherlands

[6] Univ St Radboud, Med Ctr, Nijmegen, Netherlands

[7] Antoni Van Leeuwenhoek Huis, Dept Neurol, Amsterdam, Netherlands

[8] Antoni Van Leeuwenhoek Huis, Dept Clin Chem, Amsterdam, Netherlands

来源：

NEUROLOGY | 2005年 / 65卷 / 07期

关键词：

D O I：

10.1212/01.wnl.0000178981.39984.c2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The authors determined the levels of vascular endothelial growth factor (VEGF) and urokinase-type plasminogen activator (uPA) in the CSF of patients with leptomeningeal metastases (LM; n = 53), cancer patients without LM (n = 18), and subjects without malignancy (n = 25). Median levels of uPA and VEGF were significantly higher in patients with LM, supporting the hypothesis that angiogenesis contributes to LM. VEGF was negatively correlated with survival in patients with LM, suggesting its use as a prognostic factor.

引用

收藏

页码：1120 / 1122

页数：3

相关论文

共 10 条

[1] Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases [J].

Akenami, FOT ;

Siren, V ;

Koskiniemi, M ;

Siimes, MA ;

Teravainen, H ;

Vaheri, A .

JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (07) :577-580

[2] Current diagnosis and treatment of leptomeningeal metastasis [J].

DeAngelis, LM .

JOURNAL OF NEURO-ONCOLOGY, 1998, 38 (2-3) :245-252

[3] A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols [J].

Grebenschikov, N ;

GeurtsMoespot, A ;

DeWitte, H ;

Heuvel, J ;

Leake, R ;

Sweep, F ;

Benraad, T .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1997, 12 (01) :6-14

[4] Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis:: diagnostic and prognostic value [J].

Herrlinger, U ;

Wiendl, H ;

Renninger, M ;

Förschler, H ;

Dichgans, J ;

Weller, M .

BRITISH JOURNAL OF CANCER, 2004, 91 (02) :219-224

[5]

HSU DW, 1995, AM J PATHOL, V147, P114

[6] Angiostatin prolongs the survival of mice with leptomeningeal metastases [J].

Reijneveld, JC ;

Taphoorn, MJB ;

Kerckhaert, OAJ ;

Drixler, TA ;

Boogerd, W ;

Voest, EE .

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 (01) :76-81

[7] Angiogenesis in malignant primary and metastatic brain tumors [J].

Reijneveld, JC ;

Voest, EE ;

Taphoorn, MJB .

JOURNAL OF NEUROLOGY, 2000, 247 (08) :597-608

[8] Leptomeningeal metastases: Rationale for systemic chemotherapy or what is the role of intra-CSF-chemotherapy? [J].

Siegal, T .

JOURNAL OF NEURO-ONCOLOGY, 1998, 38 (2-3) :151-157

[9] EORTC Receptor and Biomarker Study Group report: A sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts [J].

Span, PN ;

Grebenchtchikov, N ;

Geurts-Moespot, J ;

Westphal, JR ;

Lucassen, AMJ ;

Sweep, CGJ .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2000, 15 (02) :184-191

[10] Vascular endothelial growth factor in CSF - A biological marker for carcinomatous meningitis [J].

Stockhammer, G ;

Poewe, W ;

Burgstaller, S ;

Deisenhammer, F ;

Muigg, A ;

Kiechl, S ;

Schmutzhard, E ;

Maier, H ;

Felber, S ;

Schumacher, P ;

Gunsilius, E ;

Gastl, G .

NEUROLOGY, 2000, 54 (08) :1670-1675